


FORM PTO-1390 (REV 11-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER <b>117-347</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/787633</b> <small>Unknown</small>
INTERNATIONAL APPLICATION NO. <b>PCT/GB99/03180</b>	INTERNATIONAL FILING DATE <b>22 September 1999</b>	PRIORITY DATE CLAIMED <b>22 September 1998</b>
TITLE OF INVENTION <b>TREATMENT OF INFECTION</b>		
APPLICANT(S) FOR DO/EO/US <b>WILSON et al.</b>		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
- ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
- ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
- ☒ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
- ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
  - ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - ☒ has been transmitted by the International Bureau.
  - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- ☒ Amendments to the claims of the International Application under PCT Article 34.
  - ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - ☒ have been transmitted by the International Bureau.
  - ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
  - ☐ have not been made and will not be made.
- ☐ A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. To 16. Below concern document(s) or information included:**

- ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
- ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
- ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
- ☐ A substitute specification.
- ☐ A change of power of attorney and/or address letter.
- ☒ Other items or information attached: IDS; PTO 1449 with copies of listed documents; paper & computer readable copies of Sequence Listing; Letter re: Sequence Listing  
☒ This application is entitled to "Small entity" status. ☐ "Small entity" statement attached.

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/787633</b>		INTERNATIONAL APPLICATION NO. <b>PCT/GB99/03180</b>		ATTORNEY'S DOCKET NUMBER <b>117-347</b>															
17. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b> PTO USE ONLY															
<b>BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):</b> -- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....\$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....\$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO .....\$710.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....\$690.00 -- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) .....\$100.00  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$	860.00														
				Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).	\$	130.00													
				<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:20%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:20%;">NUMBER EXTRA</th> <th style="width:20%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td style="text-align: center;">8</td> <td style="text-align: center;">-20 =</td> <td style="text-align: center;">0</td> </tr> <tr> <td>Independent Claims</td> <td style="text-align: center;">4</td> <td style="text-align: center;">-3 =</td> <td style="text-align: center;">1</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total Claims	8	-20 =	0	Independent Claims	4	-3 =	1	\$	0.00
				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE												
				Total Claims	8	-20 =	0												
Independent Claims	4	-3 =	1																
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)		\$270.00	\$	0.00															
<b>TOTAL OF ABOVE CALCULATIONS =</b>			\$	<b>1070.00</b>															
Reduction by 1/2 for filing by small entity, if applicable. Small entity status must also be asserted. (Note 37 C.F.R. 1.9, 1.27, 1.28).				\$	535.00														
<b>SUBTOTAL =</b>				\$	<b>535.00</b>														
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).				\$	0.00														
<b>TOTAL NATIONAL FEE =</b>				\$	<b>535.00</b>														
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property				\$	0.00														
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)				\$	0.00														
<b>TOTAL FEES ENCLOSED =</b>				\$	<b>535.00</b>														
				Amount to be:															
				refunded	\$														
				Charged	\$														
a. <input checked="" type="checkbox"/> A check in the amount of \$535.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees. A duplicate copy of this form is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed. d. <input checked="" type="checkbox"/> The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application. <b>NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>																			
<b>SEND ALL CORRESPONDENCE TO:</b>  NIXON & VANDERHYE P.C. 1100 North Glebe Road, 8 <sup>th</sup> Floor Arlington, Virginia 22201 Telephone: (703) 816-4000																			
 _____ SIGNATURE																			
<b>B. J. Sadoff</b> NAME																			
<b>36,663</b> REGISTRATION NUMBER																			
<b>March 21, 2001</b> Date																			

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

WILSON et al.

Atty. Ref.: 117-347

Serial No. Unknown

Group:

Filed: March 21, 2001

Examiner:

For: TREATMENT OF INFECTION

\* \* \* \* \*

March 21, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**PRELIMINARY AMENDMENT**

Preliminarily amend the above-identified application as follows.

**IN THE SPECIFICATION**

Amend the specification as follows.

Insert the attached Sequence Listing in place of the originally-filed copy of the same.

**IN THE CLAIMS**

Please cancel claims 1-11 without prejudice or disclaimer and add claims 12-19 as follows:

--12. (new) A method of identifying a compound that inhibits the growth of an organism comprising the *ycf 24* gene, the method comprising

- (i) contacting a test compound with the *ycf 24* gene product, and
  - (ii) determining whether the test compound inhibits the activity of or binds to the product, any such binding or inhibition being indicative that the compound inhibits the growth of the organism.
13. (new) The method according to claim 12 in which the organism is a malaria parasite.
14. (new) A method of identifying a compound that inhibits the growth of an organism comprising the *ycf 24* gene, the method comprising
- (i) contacting a test compound with a test construct comprising a *ycf 24* promoter operably linked to a coding sequence, and
  - (ii) determining whether the test compound inhibits expression driven by the promoter, any such inhibition being indicative that the compound inhibits the growth of the organism.
15. (new) The method according to claim 14 in which the organism is a malaria parasite.
16. (new) A pharmaceutical composition comprising an inhibitor of *ycf 24* gene product expression and/or activity and a pharmaceutically acceptable carrier or diluent.
17. (new) The pharmaceutical composition according to claim 16 wherein the inhibitor is an inhibitor of the growth of a malaria parasite.
18. (new) A method of preventing or treating infection by an organism comprising the *ycf 24* gene in a patient, said method comprising administering to the patient an inhibitor of *ycf 24* gene product expression and/or activity.
19. (new) The method according to claim 18 in which the organism is a malaria parasite.--

#### **REMARKS**

The above amendments are made to place the claims in a more traditional format. Claims 12-19 are pending.

**WILSON** et al.

Serial No. **Unknown**

U.S. National Phase of PCT/GB99/03180


The specification has been amended to include the attached Sequence Listing. The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added. A separate Letter stating the same is attached.

An early and favorable Action on the merits is requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

BJS:ms

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

WILSON et al.

Atty. Ref.: 117-347

Serial No. Unknown

Group:

Filed: March 21, 2001

Examiner:

For: TREATMENT OF INFECTION

\* \* \* \* \*

March 21, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**LETTER**


The attached paper and computer readable copies of the Sequence Listing are the same.

No new matter has been added.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

BJS:ms  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

WILSON et al.

Atty. Ref.: 117-347

Serial No. 09/787,633

Group:

Filed: March 21, 2001

Examiner:

For: TREATMENT OF INFECTION

\* \* \* \* \*

May 23, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


**SMALL ENTITY CLAIM**

Please accept the Small Entity claim made herein with regard to the above-identified application.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

BJS:eaw  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

TREATMENT OF INFECTIONField of the invention

This invention relates to inhibitors of the expression and activity of a gene product and screening methods for the identification of such inhibitors. It further relates to the use of said inhibitors in the treatment of infection by an organism, such as a malaria parasite.

Background to the invention

The malaria parasite and related Apicomplexans are unusual amongst non-photosynthetic organisms in that they possess two forms of organellar DNA, typically a property of plants. One form of organellar DNA is mitochondrial DNA and the other is a 35 kb circle of DNA present in a plastid. The plastid is thought to be of prokaryotic origin. The *ycf 24* gene<sup>1,2</sup> which is present on the DNA of this plastid corresponds to a well conserved gene which is also found in red algal plastids<sup>3</sup> and various bacteria, including *E. coli*.

The plastid genome of Apicomplexans<sup>4</sup> is distinctive from, but broadly resembles that of the parasitic higher plant *Epifagus virginiana*<sup>5</sup>. It has been suggested that the *raison d'être* for maintenance of vestigial plastid genomes is the small number of open reading frames they carry besides the highly selected set of genes dedicated to the organellar expression system<sup>6</sup>. Unlike Apicomplexans, *Epifagus* does not carry the *ycf 24* gene on its plastid genome, suggesting that either the vestigial organelles have different functions, or a stochastic process determines gene loss or transfer to the nucleus.

The high level of conservation of *ycf 24* (~50% amino acid identity of the putative encoded peptide product with other orthologs) suggests that it is under strong



-2-

selective pressure and likely to have a general function.

Organelle transfection is not available in Apicomplexans. Therefore "knockouts" can only be tested in surrogate organisms.

#### Summary of the invention

The present inventors have disrupted *ycf 24* in both *Synechocystis* sp. strain PCC6803 and *E. coli*<sup>7</sup>.

Disruption of all the copies of the *ycf 24* gene in these organisms was found to be lethal. Disruption of some of the copies of *ycf 24* was found to give a 'ragged' phenotype in *Synechocystis* and appeared to cause a delay in or interfere in the process of septation during cell division. Thus *ycf 24* is an essential gene and appears to play a role in replication. The present invention is based on the inhibition of the expression or activity of the *ycf 24* product to inhibit the growth of an organism in vivo or ex vivo.

Thus the invention provides an inhibitor of *ycf 24* gene product expression and/or activity for use in a method of treatment of the human or animal body by therapy. Such an inhibitor is useful in particular in the treatment of infection by an organism, such as a malaria parasite. The invention also provides a method of inhibiting the growth of an organism comprising contacting the organism ex vivo with an inhibitor of *ycf 24* gene product expression and/or activity.

Screens may be carried out to identify the inhibitor. Accordingly the invention provides a method of identifying a compound that inhibits the growth of an organism comprising

- (i) contacting a test compound with the *ycf 24* gene product, and
- (ii) determining whether the test compound inhibits the

-3-

activity of or binds to the product, any such binding or inhibition being indicative that the compound inhibits the growth of the organism.

The invention also provides a method of identifying a compound that inhibits the growth of an organism comprising

(i) contacting a test compound with a test construct comprising a *ycf 24* promoter operably linked to a coding sequence,

(ii) determining whether the test compound inhibits expression driven by the promoter, any such inhibition being indicative that the compound inhibits the growth of the organism.

The invention further provides a pharmaceutical composition comprising an inhibitor of the invention and a pharmaceutically acceptable carrier or diluent.

As noted above the inhibitor may be used to treat an infection by an organism and therefore the invention provides a method of treating a host suffering from an infection by an organism, which method comprises administering to the host a therapeutically effective amount of an inhibitor of *ycf 24* product expression and/or activity.

#### Brief description of the drawings

The invention is illustrated by the accompanying drawings in which:

Fig.1 shows phenotypic characters of wild type (WT), ragged transformant (R) and smooth mutant forms (S) of *Synechocystis* sp. : a) Colony shape and size; an enlargement is inserted in R, b) Scanning electron micrographs of whole cells - bar = 10µm, c) Cross-sections showing plaques - arrow, d) Whole cells with and without 4',6-diamindino-2-phenylindole (DAPI)-staining. Arrows point to mis-segregation.

-4-

Fig.2 shows a Southern blot of DNA from *Synechocystis* sp., restricted with *Hind* III and hybridized with wild type (WT) *ycf* 24. The sizes expected for restriction fragments from WT (lane 4) and clones of heteroplasmic transformants (lanes 1-3) are given in the diagram below.

Fig.3 shows an effect of over-expression of *ycf* 24 in *E.coli*. Fig. 3a shows nucleoids stained with DAPI in an uninduced culture of *E.coli* and Fig. 3b shows nucleoids stained with DAPI after induction of over-expression.

#### Detailed description of the invention

The inhibitor can be used to inhibit the growth of a unicellular or multicellular organism in vivo or ex vivo. The organism may be a prokaryote or a eukaryote. The organism comprises the *ycf* 24 gene. In the case of a eukaryote the nuclear genome of the organism may contain the *ycf* 24 gene or the organism may contain an organelle which contains DNA comprising the *ycf* 24 gene. Such an organelle is generally of prokaryotic origin, for example algal origin, and may be a plastid.

The organism may be a protozoa, such as an Apicomplexan, for example of clade plasmodium, piroplasm, sarcocystan or coccidium. The organism may be *Plasmodium falciparum*. The organism may be an alga. The organism may be a bacterium, such as a cyanobacterium, mycobacterium or *E. coli*. The organism may be free-living or a pathogen of humans and/or animals. It may be an intracellular or extracellular pathogen.

The *ycf* 24 gene product is generally one which can be expressed from the coding region of:

(a) the polynucleotide sequence of SEQ ID NO: 1, 2 or 3

-5-

or a fragment thereof; or

(b) polynucleotides which can selectively hybridise to the coding region of (a) of a fragment thereof; or

(c) polynucleotides which, but for the degeneracy of the genetic code, would hybridise to (a) or (b).

The polynucleotides of (b) may selectively hybridise under conditions of medium to high stringency, for example 0.03M NaCl and 0.03M sodium citrate at from 50 to 60 degrees centigrade.

Thus the polynucleotide from which the *ycf* 24 product is expressed generally has at least 70%, preferably at least 95, 97 or 99% sequence identity to the coding sequence of SEQ ID NO: 1, 2, or 3 over a region of at least 20, preferably at least 30, for instance at least 46, 60 or 100 or more contiguous nucleotides.

The *ycf* 24 product generally has at least 50% sequence identity to the amino acid sequences shown is SEQ ID NO: 1, 2, or 3, preferably at least 80 or 90% and more preferably at least 95, 97 or 99% over a region of at least 20, preferably at least 30, for instance at least 46, 60, 100 or more contiguous amino acids. The term *ycf* 24 product includes fragments of the amino acid sequences of SEQ ID NO: 1, 2 or 3 or of the homologous sequences discussed above. Suitable fragments will be at least 5, 10, 20 or 40 amino acids in size, for example at least 60 or 100 amino acids in size. Generally the *ycf* 24 product has *ycf* 24 product activity, and would generally be able to complement the activity of a naturally occurring *ycf* 24 product.

Any suitable inhibitor of *ycf* 24 product activity may be used in the present invention. The inhibitor may bind in a reversible or irreversible manner. An irreversible inhibitor would dissociate very slowly from the *ycf* 24 product because it would be very tightly

-6-

bound, either covalently or non-covalently. Reversible binding, in contrast with irreversible binding, is characterised by a rapid dissociation of the *ycf 24* product-inhibitor complex.

5 As noted above the invention provides a method of identifying a compound that inhibits the activity of *ycf 24* product. *ycf 24* product for use in this method can be obtained, for example, recombinantly by any method known in the art. The nucleotide sequences of the *ycf 24*  
10 genes of *Plasmodium falciparum*, *Synechocystis* Sp strain pCC6803 and *E.coli* are provided herein as SEQ ID NOs 1, 2 and 3 respectively. The *ycf 24* genes of other species may be identified by searching in databases for genes homologous to SEQ ID NO: 1, 2 or 3. Nucleotides with the  
15 same sequence as genes identified in a database can be made and expressed using routine methods which are known in the art. Alternatively *ycf 24* genes can be identified by probing genomic or cDNA libraries with nucleotides comprising the *ycf 24* gene or a fragment of the *ycf 24*  
20 gene and then isolating and sequencing the nucleotides identified by the probe.

Any suitable format may be used for identifying the inhibitor of the activity. In the method the *ycf 24* product is generally in a suitable buffer, which includes  
25 any suitable biological buffer that can provide buffering capability at a pH conducive to the reaction requirements of the *ycf 24* product. The *ycf 24* product may be in conditions which are similar to the physiological conditions in which it occurs naturally.

30 In the method the *ycf 24* product may be in inside a cell or outside a cell. The cell may be the cell in which the *ycf 24* product naturally occurs, or a cell in which the *ycf 24* product is expressed recombinantly. The cell may be treated with agents which permeabilise the cell

-7-

surface allowing test substances to enter the cell more readily. The *ycf* 24 product used in the method may be in the form of an extract from such cells.

5 The method may determine whether a test compound is able to bind the *ycf* 24 product, such as in a specific manner. This method may comprise allowing the *ycf* 24 product to bind to a test compound and measuring the amount of binding that occurs, such as by measuring the amount of *ycf* 24 bound to the compound. The amount of  
10 binding may be determined by measuring a characteristic of the *ycf* 24 product that changes upon binding, such as spectroscopic changes.

The assay format may be a 'band shift' system. This involves determining whether a test compound advances or  
15 retards the *ycf* 24 product on gel electrophoresis relative to the *ycf* 24 product in the absence of the compound.

The method may be a competitive binding assay. This determines whether the test compound is able to inhibit  
20 the binding of the *ycf* 24 product to a substance which is known to bind to the *ycf* 24 product, such as an antibody specific for product. This method allows test compounds to be identified which are 'analogues' of *ycf* 24 product.

The competitive binding system may comprise  
25 (i) incubating the *ycf* 24 product with a test compound and a labelled reference compound that is known to bind the product;  
(ii) determining the amount of the labelled reference compound that is bound to the product; and  
30 (iii) comparing the amount of bound labelled reference compound determined in step (ii) with the amount of said compound that binds to the product in the absence of the test compound;  
wherein any reduction in the binding of the labelled

-8-

reference compound in the presence of the test compound compared to the binding in the absence of the test compound shows that the test compound is competing with the reference compound for binding to the product. This indicates that the test compound could be an inhibitor of *ycf 24* product activity.

The amount of the labelled reference compound bound to the *ycf 24* product may be measured directly or indirectly. A direct measurement may be carried out by removing assay mixture containing the unbound labelled reference compound and measuring the amount of label that is in the product fraction. Alternatively, the amount of labelled reference compound bound to the product could be determined indirectly by measuring the amount of label remaining in the assay solution after removal of the product fraction, which will be inversely related to the amount that has bound to the product.

In a competitive binding assay system, the *ycf 24* product may be immobilised on a solid support or may be in solution. The use of immobilised product has the advantage that, after the binding reaction is complete, the product/labelled reference compound complex may be separated from the labelled reference compound that remains in solution by simply removing the solution away from the solid support. If, on the other hand, the product is not immobilised during the assay but rather is in solution, then it will generally be necessary to devise a means for separating the product/labelled reference compound complex from the uncomplexed reference compound before measuring the amount of label. Such separation could be achieved, for example, by precipitating the product using an antibody to the product or by using a non-specific precipitation technique.

Suitable labels for use in the assay systems

-9-

according the invention are well-known in the art. The reference compound which is know to bind the *ycf* 24 product may be an antibody.

5 An antibody to *ycf* 24 product may be produced by raising antibody in a host animal against the whole *ycf* 24 product or an antigenic epitope thereof (hereinafter "the immunogen"). Methods of producing monoclonal and polyclonal antibodies are well-known. A method for producing a polyclonal antibody comprises  
10 immunising a suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises  
15 immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour cells (Kohler and Milstein, Nature 256, 495-497, 1975).

20 An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or  
25 immunocompromised host. Human antibody may be prepared by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

30 For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled, for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier  
35 molecule is typically a physiologically acceptable



-10-

carrier. The antibody obtained may be isolated and, if desired, purified.

Any suitable inhibitor of expression of *ycf 24* product may be employed in the present invention.

5 Preferably the inhibitor is a specific inhibitor of transcription from the *ycf 24* gene, and does not inhibit transcription from other genes.

10 The inhibitor may inhibit transcription or translation of *ycf 24* product. The inhibitor may bind to the *ycf 24* gene either 5' to the coding sequence, to the coding sequence or 3' to the coding sequence. Thus the inhibitor may bind to the *ycf 24* promoter, and inhibit the initiation of transcription. The inhibitor may bind and inhibit the action of a protein which is required for transcription from the *ycf 24* gene. The inhibitor may bind to the untranslated or translated regions of the *ycf 24* mRNA. This could prevent the initiation of translation. Alternatively the inhibitor could bind to a protein which associates with the untranslated region and prevent the protein associating with the untranslated region.

25 Any suitable assay format may be used for identifying an inhibitor of *ycf 24* expression. The invention provides a method for identifying an inhibitor of *ycf 24* expression comprising:

(i) contacting a compound with a nucleic acid comprising a *ycf 24* promoter operably linked to a coding sequence; and  
(ii) determining whether the compound inhibits expression driven by the promoter.

30 Generally this method is carried out in conditions which in the absence of the test compound lead to expression of the coding sequence from the nucleic acid. The nucleic acid may also comprise other untranscribed or untranslated regions of the *ycf 24* gene. The coding

-11-

sequence typically encodes a protein that is able to act as a reporter of expression. The assay may be carried out in a cell which harbours the nucleic acid. The substance may be tested with any other known promoter to test the possibility that the test substance is a general inhibitor of gene expression.

Any reporter polypeptide may be used, for example GUS or GFP. GUS is assayed by measuring the hydrolysis of a suitable substrate, for example 5-bromo-4-chloro-3-indolyl- $\beta$ -D-glucuronic acid (X-gluc) or 4-methylumbelliferyl- $\beta$ -glucuronide (MUG). The hydrolysis of MUG yields a product which can be measured fluorometrically. GFP is quantified by measuring fluorescence at 590nm after excitation at 494nm. These methods are well known to those skilled in the art.

Alternatively the coding sequence may be the *ycf 24* coding sequence itself, or a fragment of this sequence. The expression of the *ycf 24* product may be measured by for example, Northern/RNA blotting, Western/antibody blotting, RNA in situ hybridization or immunolocalisation. Thus the method for identifying an inhibitor of expression of *ycf 24* product may be performed on a cell which naturally harbours the *ycf 24* gene, or an extract from such a cell.

Suitable candidate substances which may be inhibitors and which can be tested in the methods discussed above include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for *ycf 24* product. Furthermore, combinatorial libraries, defined chemical identities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries (e.g. phage display libraries) may also be tested. The candidate substances may be chemical

-12-

compounds. Batches of the candidate substances may be used in an initial screen of, for example, ten substances per reaction, and the substances of batches which show inhibition tested individually.

5

#### Antisense inhibitors

10

As noted above the expression of *ycf 24* in a cell may be reduced by the presence in that cell of a compound which can bind to the *ycf 24* mRNA. Therefore a polynucleotide which is capable of hybridizing to *ycf 24* mRNA can constitute an appropriate inhibitor of *ycf 24* expression.

15

The polynucleotide may be antisense to the *ycf 24* mRNA. Such a polynucleotide may be capable of hybridising to *ycf 24* mRNA and may thus inhibit the expression of *ycf 24* product by interfering with one or more aspects of *ycf 24* mRNA metabolism including processing, translation and metabolic turnover.

20

The antisense polynucleotide may be RNA. This may hybridise to the *ycf 24* mRNA to form an RNA-RNA duplex which may cause direct inhibition of translation and/or the destabilization of the target message, for example, rendering susceptibility to nucleases.

25

Such a polynucleotide may hybridize to all or part of the *ycf 24* mRNA. Typically the antisense polynucleotide hybridizes to the ribosome binding region or the coding region of the *ycf 24* mRNA. The polynucleotide may be complementary to all of or a region of the *ycf 24* mRNA. For example, the polynucleotide may be the exact complement of all or a part of *ycf 24* mRNA.

30

However, absolute complementarity is not required and polynucleotides which have sufficient complementarity to form a duplex having a melting temperature of greater than 20°C, 30°C or 40°C under physiological conditions are particularly suitable for use in the present invention.

-13-

The polynucleotide may be a polynucleotide which hybridises to the *ycf* 24 mRNA under conditions of medium to high stringency such as 0.03M sodium chloride and 0.03M sodium citrate at from about 50 to about 60 degrees centigrade.

It is preferred that the polynucleotide hybridizes to all or part of the region of the *ycf* 24 mRNA corresponding to the coding sequence defined by nucleotides 26 to 1435 of SEQ ID NO:1. However, the polynucleotide may hybridise to all or part of the 5'- or 3'-untranslated region of the mRNA. The polynucleotide will typically be from 6 to 40 nucleotides in length. Preferably it will be from 12 to 20 nucleotides in length. The polynucleotides may be at least 40, for example at least 60 or at least 80, nucleotides in length and up to 100, 200, 300, 400, 500, 600 or 700 nucleotides in length or even up to a few nucleotides, such as five or ten nucleotides, shorter than SEQ ID NO: 1, 2 or 3.

When the polynucleotide is an antisense RNA it may be expressed in a cell from a recombinant replicable vector. Such a replicable vector comprises a polynucleotide which when transcribed gives rise to antisense RNA.

Thus the antisense polynucleotide may be provided by delivering such a vector to the cell and allowing transcription from the vector to occur. Such a vector is also understood to an inhibitor of *ycf* 24 expression in this specification. Generally on the vector the polynucleotide giving rise to the antisense RNA is operably linked to a control sequence which is capable of providing for the transcription of the polynucleotide giving rise to the antisense RNA. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence

-14-

"operably linked" to a sequence giving rise to an antisense RNA is ligated in such a way that transcription of the sequence is achieved under conditions compatible with the control sequences.

5 The vector may be for example, a plasmid or virus vector provided with an origin of replication, optionally a promoter for transcription to occur and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example an ampicillin  
10 resistance gene in the case of bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used in vitro, for example for the production of antisense RNA or used to transfect or transform a host cell. The term 'host cell' refers either to the organism  
15 whose growth it is desired to inhibit, or a human or animal cell which can be infected by the organism. Thus the host cell may be an infected cell. The vector may also be adapted to be used in vivo, for example in a method of gene therapy.

20 Promoters/enhancers and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. For example, mammalian promoters, such as b-actin promoters, may be used. Tissue-specific promoters, in particular  
25 neuronal cell specific promoters (for example the tyrosine hydroxylase (TH), L7, or neuron specific enolase (NSE) promoters), are especially preferred. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR),  
30 the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, herpes simplex virus promoters or adenovirus promoters. All these promoters are readily available in the art. Preferred promoters are tissue specific promoters such as  
35 the casein gene promoter.

-15-

The vector may further include sequences flanking the polynucleotide giving rise to antisense RNA which comprise sequences homologous to eukaryotic genomic sequences, preferably mammalian genomic sequences, or viral genomic sequences. This will allow the introduction of the polynucleotides of the invention into the genome of eukaryotic cells or viruses by homologous recombination. In particular, a plasmid vector comprising the expression cassette flanked by viral sequences, for example HSV1 or HSV2 sequences, can be used to prepare a viral vector, for example an HSV vector, suitable for delivering the polynucleotides of the invention to a mammalian cell. Other examples of suitable viral vectors include retroviruses, including lentiviruses, adenoviruses and adeno-associated viruses. Gene transfer techniques using these viruses are known to those skilled in the art. Retrovirus vectors for example may be used to stably integrate the polynucleotide giving rise to the antisense RNA into the host genome. Replication-defective adenovirus vectors by contrast remain episomal and therefore allow transient expression.

Antisense polynucleotides may be chemically modified. This may enhance their resistance to nucleases and may enhance their ability to enter cells. For example, phosphorothioate oligonucleotides may be used. Other deoxynucleotide analogs include methylphosphonates, phosphoramidates, phosphorodithioates, N3'P5'-phosphoramidates and oligoribonucleotide phosphorothioates and their 2'-O-alkyl analogs and 2'-O-methylribonucleotide methylphosphonates.

Alternatively mixed backbone oligonucleotides (MBOs) may be used. MBOs contain segments of phosphothioate oligodeoxynucleotides and appropriately placed segments of modified oligodeoxy- or oligoribonucleotides. MBOs have segments of phosphorothioate linkages and other segments of

-16-

other modified oligonucleotides, such as methylphosphonate, which is non-ionic, and very resistant to nucleases or 2'-O-alkyloligoribonucleotides.

An inhibitor of *ycf 24* expression and/or activity is one which produces a measurable reduction in *ycf 24* expression and/or activity in the methods described above. Preferred substances are those which inhibit *ycf 24* expression and/or activity by at least 10%, at least 20%, at least 30%, at least 40% at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% at a concentration of the inhibitor of  $1\mu\text{g ml}^{-1}$ ,  $10\mu\text{g ml}^{-1}$ ,  $100\mu\text{g ml}^{-1}$ ,  $500\mu\text{g ml}^{-1}$ ,  $1\text{mg ml}^{-1}$ ,  $10\text{mg ml}^{-1}$  or  $100\text{mg ml}^{-1}$ . The percentage inhibition represents the percentage decrease in expression/activity in a comparison of assays in the presence and absence of the test substance. Any combination of the above mentioned degrees of percentage inhibition and concentration of inhibitor may be used to define an inhibitor of the invention, with greater inhibition at lower concentrations being preferred.

When used in vivo or in vitro the inhibitor inhibits the growth of the organism. Generally the inhibitor will decrease the rate of cell division of the organism. Generally the inhibitor will decrease the number of divisions that occur in a unit of time by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% at a concentration of inhibitor of  $1\mu\text{g ml}^{-1}$ ,  $10\mu\text{g ml}^{-1}$ ,  $100\mu\text{g ml}^{-1}$ ,  $500\mu\text{g ml}^{-1}$ ,  $1\text{mg ml}^{-1}$ ,  $10\text{mg ml}^{-1}$  or  $100\text{mg ml}^{-1}$ .

If the organism is one in which the *ycf 24* gene is present in an organelle then the inhibitor generally decreases the rate of division of that organelle. The inhibitor may also disrupt cell or organelle division in other ways, such as causing abnormal septation or mis-segregation of DNA. The inhibitor may also disrupt the structure of the organism, such as giving the organism a 'ragged' appearance. The inhibitor may cause the death of

-17-

the organism.

Candidate substances which show activity in assays such as those described herein can then be tested on the organism in question. The inhibitor may or may not be toxic towards humans or animals. The inhibitor may thus be used as an antibiotic.

The inhibitors of *ycf 24* expression and/or activity or the vectors described above may be used to treat infections by an organism and, in particular, malaria. The condition of a patient suffering from an infection can therefore be improved by administration of such an inhibitor. A therapeutically effective amount of such an inhibitor may be given to a human patient in need thereof.

The formulation of inhibitor or vector for use in preventing or treating infection by an organism will depend upon factors such as the nature of the substance identified, whether a pharmaceutical or veterinary use is intended, etc. In order to be administered to a patient, the compound will be provided in the form of a pharmaceutical composition containing the inhibitor or vector and a pharmaceutically acceptable carrier or diluent. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. Typical oral dosage compositions include tablets, capsules, liquid solutions and liquid suspensions. For example it may be formulated for parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration.

The dose of inhibitor may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient. A suitable dose may however be from



-18-

0.1 to 100 mg/kg body weight such as 1 to 40 mg/kg body weight, for example, to be taken from 1 to 3 times daily.

The oral route is preferred because this is generally the most convenient route for a patient to take regular doses of the compound without the assistance of a physician. However, the inhibitor or vector may be administered by direct injection into the site to be treated.

The inhibitor or vector may be used in either the treatment of an existing infection by the organism or in the prevention of such an infection from occurring in the first place.

The vectors giving rise to antisense RNA of the invention may be administered directly as a naked nucleic acid construct. Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques, for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam<sup>TM</sup> and transfectam<sup>TM</sup>). These agents may also enhance the uptake of the constructs by the organism.

The pharmaceutical composition may be formulated to aid delivery of the inhibitor or vector to the organism whose growth is to be inhibited. In particular it may be formulated to deliver the inhibitor or vector to the cell type which is infected or to the compartment in the human or animal cell which is infected by the organism. It may be formulated to deliver the inhibitor or vector to the organelle in the organism where *ycf 24* product or mRNA is present.

When the pharmaceutical composition comprises viral vector for gene therapy it may be administered in such a way that the vector is incorporated into cells at an appropriate area. The amount of virus administered is in

-19-

the range of from  $10^4$  to  $10^8$  pfu, preferably from  $10^5$  to  $10^7$  pfu, more preferably about  $10^6$  pfu for herpes viral vectors and from  $10^6$  to  $10^{10}$  pfu, preferably from  $10^7$  to  $10^9$  pfu, more preferably about  $10^8$  pfu for adenoviral vectors. When  
5 injected, typically 1-2 ml of virus in a pharmaceutically acceptable suitable carrier or diluent is administered. When the polynucleotide is administered as a naked nucleic acid, the amount of nucleic acid administered is typically in the range of from 1  $\mu$ g to 10 mg.

10 Where the polynucleotide giving rise to the antisense RNA is under the control of an inducible promoter, it may only be necessary to induce gene expression for the duration of the treatment. Once the condition has been treated, the inducer is removed and expression of the  
15 polypeptide of the invention ceases. This will clearly have clinical advantages. Such a system may, for example, involve administering the antibiotic tetracycline, to activate gene expression via its effect on the tet repressor/VP16 fusion protein.

20 The use of tissue-specific promoters will be of assistance in the treatment of disease using the vectors of the invention. It will be advantageous to be able express inhibitors of *ycf 24* in only the relevant affected cell types, especially where such inhibitors are toxic when  
25 expressed in other cell types.

When the inhibitor is used to inhibit the growth of an organism ex vivo the organism may or may not be a pathogen of humans or animals. The inhibitor may be used to treat land, water or food containing the organism.

30 The following Examples illustrate the invention:

#### Example 1

##### Gene disruption of *ycf 24*, transformation and selection

A central segment of the wild type gene (*slr0074*)  
35 from *Synechocystis* sp., strain pCC6803, (delineated by

-20-

two *Hind*III sites ~1.0 kb apart) was amplified from genomic DNA by PCR using two oligonucleotide primers based on the known sequence (Accession no. S76598): 5' CTC CGC CCC TAA GCA AAG TAA GAA A and 5' TGA TCC TCG CCA ATT TTG GAA GTG GA. The amplified fragment was restricted with *Hind*III and cloned into pUC9 to give pUC9/slr. The sequence of both ends of the insert was confirmed in recombinants grown in Epicurian SURE cells. To disrupt the gene, a kanamycin resistance gene ( $k^r$ ) isolated from a modified bluescript vector (pBSHdSpl, was blunt-ended with the Klenow fragment and cloned into a unique *Xba*I site in the *ycf* 24 insert to give pUC9/slr/ $k^r$ . Recombinants in XL1-blue MRF' cells were selected using kanamycin. Disruption of the *ycf* 24 insert was confirmed by sequencing the junction regions.

Wild type (WT) cells of *Synechocystis* sp. strain PCC 6803 were transfected by incubation with light at 30°C for 4 hr with vector DNA carrying the disrupted *ycf* 24 gene (1-5 µg in 10 µl water). Selection and growth were carried out on BG11 plates under photo-autotrophic conditions at 30°C. Several rounds of replication were allowed over 3 days before recombinants were selected by overlaying with kanamycin (50 µg/ml). This killed most of the cells but transformants emerged after a delay. Every 10-14 days thereafter, transformants were picked and re-plated to allow segregation of mutant cells. For growth comparisons in the absence of selection, WT cells were plated at the same time on BG11 (their growth was inhibited totally by kanamycin at 50 µg/ml).

## Example 2

### Gene Disruption in *E. coli*

Disruption of *ycf* 24 in *E. coli* was carried out along similar lines, but in this case disruption was with the *aadA* gene for streptomycin resistance ( $S^r$ ). *ycf* 24 from *E.*

-21-

*coli* was amplified using primers based on the accession no. D90811 with added terminal restriction sites: 5' GAG CTC GGA ATT CGC ATG TGG CTG TGG CGA AAG and 3' GAG CTC GGG ATC CTT ATC CGA CGC TGT GTT CAA G. The *E. coli aadA* gene was introduced at a *BsgI* restriction site near the centre of *ycf 24* and cloned into the bluescript vector pBSKS<sup>+</sup>. The construct was linearized for transformation and to allow homologous recombination in *E. coli* LE392 host cells. The linearized recombinant plasmid pBSKS<sup>+</sup>/*ycf24*/*S<sup>r</sup>* was transfected into *E. coli* by heat shock but no homologous recombinants were found from the primary normal size colonies; a few antibiotic resistant colonies were recovered that carried circular episomes likely to have arisen from re-ligation of the construct. After 2 days incubation at 37°C small colonies were observed. Cells from these were found to be elongated (at least x3 length of host cells) but they survived for only a few generations. PCR from these colonies to determine if a "knock-out" had occurred was unsuccessful.

### Example 3

#### Characterising the *Synechocystis* transformants

WT *Synechocystis* and transformants carrying an homologous form of *ycf 24* interrupted by a kanamycin resistance gene (*k<sup>r</sup>*) were plated on BG-11 agar. The WT cells formed colonies visible to the naked eye within 4 days, whereas it took 2 weeks for transformants to appear under selection with kanamycin (50 µg ml<sup>-1</sup>). Colonies of transformants were small and "ragged" in outline in contrast to the larger, smooth-contoured WT colonies (Fig. 1a). DNA extracted from cloned transformants was hybridized in Southern blots with WT *ycf 24* and found to be heteroplasmic, the copy numbers of the disrupted and WT forms of *ycf 24* being approximately equal as judged from

-22-

the intensity of the hybridization signals (Fig. 2). Relaxation of kanamycin selection on heteroplasmic transformants resulted in vigorously growing, smooth-contoured colonies - "revertants", confirming that the heteroplasmic state was growth-limiting. These observations were confirmed by additional transformations, including one using disruption with a spectinomycin resistance gene instead of kanamycin. Transformants homoplasmic for the disrupted form of *ycf 24* were never recovered, even after prolonged selection with kanamycin at 50 or 100  $\mu\text{g ml}^{-1}$  and homoplasmy is inferred to be lethal.

Longer-term selection of "ragged" transformants on kanamycin also gave rise to rapidly growing colonies with smooth contours. However, hybridization on Southern blots showed these remained heteroplasmic for the disrupted gene and we refer to these as "smooth" suppressors. DNA from cloned "smooth" suppressors was used to transform both WT and "ragged" heteroplasmic cells. In both cases, kanamycin selection yielded mostly "ragged" colonies but small numbers (<1%) of smooth, rapidly growing colonies were found, unlike in the original transfections.

The cells were examined by electron microscopy. Pelleted cells were pre-fixed in 0.5% neutral glutaraldehyde in 100mM cacodylate buffer, pH 7.0 for 30 min at room temperature. After gentle centrifugation, the pelleted cells were fixed in 2-3% glutaraldehyde buffer and thin sections were prepared using standard procedures. For scanning electron microscopy (SEM), cells were spread on glass slips coated in poly-L-lysine (100  $\mu\text{g ml}^{-1}$ ) and fixed in 2% glutaraldehyde. Post fixation samples were washed in ethanol and rehydrated by immersion in hexamethyl-disilizane. After overnight dessication, samples were sputter-coated with 20 nm gold (for sample conductivity) and examined by SEM.

Electron micrographic sections showed ~80% of cells

-23-

from "ragged" colonies (>100 cells examined) had electron-translucent plaques surrounding the phycobilisomes in the thylacoid membranes (Fig. 1c). The number of cells containing plaques fell to ~45% upon relaxation of kanamycin selection pressure, coincident with reversion to normal colony morphology. Because similar plaques were found in ~4% WT cells, we suggest they indicate "sick" cells rather than a direct phenotypic change following disruption of *ycf 24*.

By contrast, examination of the gross morphology of cells from "ragged" colonies by scanning electron microscopy showed a significant accumulation of cells (~35%) in the last stages of cell division ( $p = <0.001$ ), suggesting a defect in cytokinesis (Table 1 and Fig.1b). Relaxation of kanamycin selection again saw the proportion of dividing cells in the transformed cell population return to one resembling WT. A high proportion (~60%) of the "smooth" suppressor cells also accumulated at a late stage of cytokinesis, with occasional small chains of incompletely separated cells. Smooth suppressors still contained electron-opaque plaques and electron micrographic sections confirmed that suppression increased the frequency of aberrant septation in dividing cells.

Table 1

Cell type <sup>*1</sup>	% Fission			P ( $X^2$ ) <sup>*3</sup>
	Early stage	Late stage	Total	
WT	10	9 <sup>±1</sup>	19	-
Ragged	21 <sup>*6</sup>	34 <sup>±1</sup>	55	<0.001
Revertant <sup>*2</sup>	8	4	12	0.9
Smooth	20	41	61	<0.001

<sup>\*1</sup> Nos. cells counted = >100/group (mean data from 2 exp.)

-24-

\*<sup>2</sup> Ragged transformants grown without kanamycin selection

\*<sup>3</sup> Chi-square comparison with WT

DNA was stained with 4',6-diamindino-2-phenylindole (DAPI) at 0.01µg ml<sup>-1</sup>, following a protocol similar to that described<sup>15</sup>. When stained with DAPI, the nucleoids of WT cells were highly uniform in appearance (Fig.1d). Most WT cells (~82%) were not in division and only a few dead cells (unstained) were present. DAPI-staining of cells from "ragged colonies" was much more variable, ranging from cells that looked like WT to a large number (~50%) of dead or dying cells that stained less intensely. The latter included >50% of those in division. Although nucleoid segregation had occurred in many of these cells, in ~40% the DNA had mis-segregated (ie. one daughter cell was without DNA or carried less DNA as judged by staining intensity); altered autofluorescence under UV light indicated these were dying cells. DAPI-stained "smooth" suppressants also were distinctive. About half of the cells (both dividing and non-dividing) carried normal amounts of DNA but occasional cells either had no DNA (~1% dead), had undergone asymmetric DNA segregation (~1%), or had about twice as much DNA (~1%) as WT. The cells in this last group were larger than the rest (Fig. 1d). Coulter counter analysis of the size distribution of the different populations (data not shown) confirmed that the numbers of small and large cells had substantially increased in both the "ragged" and smooth isolates compared with WT. The amount of DNA per cell corresponded generally with cell size, excepting dead cells.

#### Example 4

##### Over-expression of ycf 24 in *E.coli*

The effect of over-expressing ycf 24 in *E.coli* was examined using the expresson vector pMAL-c2.

-25-

Gene amplification was carried out with primers designed to give a 5' Eco RI site and a 3' Pst I site, and the product was cloned into the pMAL-c2 expression vector (New England Biolabs). Cultures of transfectants growing exponentially in Terrific broth containing ampicillin (50 mg ml<sup>-1</sup>) were induced with 0.3-0.5 mM IPTG. Transformants expressing fusion proteins after induction at 37°C were detected by Western blotting and by immunofluorescence using antibody to the maltose binding protein tag of the fusion protein.

Filamentation was marked in such transformants.

Immunofluorescence showed a striking "zebra" pattern of the fusion protein which was mainly sequestered on either side of the nucleoids of the bacteria.

After prolonged over-expression, the bands of fusion protein appeared at other sites along the length of the extended cells where there were no nucleoids. This correlated with aberrant partition of the nucleoids. We found the nucleoids divided but did not separate, forming a clump that distorted the cell (see Fig. 3). We also noted that the first division of the nucleoids was parallel and not transverse to the cell length so that nucleoids lay side by side rather than being displaced longitudinally as is usual. Deletion analysis of the *ycf 24* gene showed that the "zebra" pattern due to deposition of the fusion protein depends on a sequence lying between amino acids 81 and 161 at the N-terminus of the protein. Secondary structure analysis of *ycf 24* indicates it probably has several domains, two of which lie in the highly conserved C-terminal half. One domain resembles a serine protease but lacks the catalytic site. Another, at the C-terminus itself, is folded like complement factor 5a.

Examination of the cells over-expressing *ycf 24* showed they contained only slightly depressed levels of the essential cell division protein FtsZ, yet no septal rings



-26-

were formed (unlike in some other nucleoid partition mutants of *E.coli*). Thus, over-expression of *ycf 24* seems to disturb formation of the septal ring complex required for cell division.

5        Our studies with *E.coli* and *Synechocystis* concur in showing that modulating the amount of *ycf 24* affects cell division. Work is in progress to ascertain the function of the protein by determining its interactions with other cellular constituents. This includes a detailed analysis  
10 of the sequence required for cellular localization which might be susceptible to disruption by an antisense approach.

**References**

1. Williamson, D.H., et al. *Mol. Gen. Genet.* **243**, 249-252 (1994).
- 5 2. Denny, P., Preiser, P., Williamson, D. & Wilson, I. *Protist* **1**, 51-59 (1998).
3. Kowallik, K.V., Stoebe, B., Schaffran, I., Kroth-Pancic, P. & Freier, U. *Plant Mol. Report.* **13**, 336-342 (1995).
- 10 4. Wilson, R.J.M., et al. *J. Mol. Biol.* **261**, 155-172 (1996).
5. Palmer, J.D. *Nature* **364**, 762-763 (1993).
6. Wolfe, K.H., Morden, C.W. & Palmer, J.D. *Proc. Natl. Acad. Sci.* **89**, 10648-10652 (1992).
- 15 7. Labarre, J., Chauvat, F. & Thuriaux, P. *J. Bacteriol.* **171**, 3449-3457 (1989).
8. Paulton, R.J.L. *J. Bacteriol.* **104**, 762-767 (1970).
9. Walker, G.C. *The SOS response of Escherichia coli*. In *Escherichia coli and Salmonella Cellular and Molecular Biology*. Vol.1 pp.1400-1416. (ASM Press, Washington D.C.) (1997).
- 20 10. Pietrokovski, S. *Prot. Sci.* **3**, 2340-2350 (1994).
11. Colston, M.J. & Davies, E.O. *Mol. Microbiol.* **12**, 359-363 (1994).
- 25 12. Jones, D.T., Taylor, W.R. & Thornton, J.M. *Nature* **358**, 86-89 (1992).
13. Fichera, M.E. & Roos, D.S. *Nature* **390**, 407-409 (1997).
14. McFadden, G.I. & Waller, R.F. *Bioessays* **19**, 1033-1040 (1997).
- 30 15. Hiraga, S., et al. *J. Bacteriol.* **171**, 1496-1505 (1989).

-1-

# SEQUENCE LISTING

```
<210> 1
<211> 1444
<212> DNA
<213> Plasmodium falciparum
<220>
<221> CDS
<222> (26)..(1435)
<220>
<221> misc_feature
<222> (1276)
<223> h represents A, T or C
```

<400> 1															
ttttattatatt ttatatataa ttatt atg ata aaa tta aaa aat ttt tta aat															52
Met Ile Lys Leu Lys Asn Phe Leu Asn															
1 5															
att tat aat tta aat tat aaa tat caa tat aaa aat aaa ata aat tta															100
Ile Tyr Asn Leu Asn Tyr Lys Tyr Gln Tyr Lys Asn Lys Ile Asn Leu															
10 15 20 25															
tat tta ata aga caa gga tta aat ata aat tta ata aaa aat tta tct															148
Tyr Leu Ile Arg Gln Gly Leu Asn Ile Asn Leu Ile Lys Asn Leu Ser															
30 35 40															
agt aat att ttt tta tat atg ttt att tat aat ttt aaa aaa tat tct															196
Ser Asn Ile Phe Leu Tyr Met Phe Ile Tyr Asn Phe Lys Lys Tyr Ser															
45 50 55															
tta aaa tta tta aat ata ttt aaa tta cct gat tgg aat ttt ttt gat															244
Leu Lys Leu Leu Asn Ile Phe Lys Leu Pro Asp Trp Asn Phe Phe Asp															
60 65 70															
tgt cca aat ata aat tat gat aat att att tat tat tct tct att tta															292
Cys Pro Asn Ile Asn Tyr Asp Asn Ile Ile Tyr Tyr Ser Ser Ile Leu															
75 80 85															
aaa gat aat aat tta ata tat tat tta aaa aat aat tta aat att gaa															340
Lys Asp Asn Asn Leu Ile Tyr Tyr Leu Lys Asn Asn Leu Asn Ile Glu															
90 95 100 105															
ttt tta gat agt ata tta ata aaa aat aat tct ata gat att ata ttt															388
Phe Leu Asp Ser Ile Leu Ile Lys Asn Asn Ser Ile Asp Ile Ile Phe															
110 115 120															
gat agt atg tct att tta cat act aca caa tat ttt tta aaa aaa tth															436
Asp Ser Met Ser Ile Leu His Thr Thr Gln Tyr Phe Leu Lys Lys Xaa															
125 130 135															

-2-

gga ata att ttt tta cct tta ttt gat att ata ttt aaa tat cct tta	484
Gly Ile Ile Phe Leu Pro Leu Phe Asp Ile Ile Phe Lys Tyr Pro Leu	
140 145 150	
tta ata aaa aaa tat tta ggt act att att tct tat aaa gat aat ttt	532
Leu Ile Lys Lys Tyr Leu Gly Thr Ile Ile Ser Tyr Lys Asp Asn Phe	
155 160 165	
ttt gct aat att aat tca ata ata ttt agt gaa gga tct ttt tgt tat	580
Phe Ala Asn Ile Asn Ser Ile Ile Phe Ser Glu Gly Ser Phe Cys Tyr	
170 175 180 185	
ata cct aaa tat gta aag tgt aat ttt aat tta tca aca tat ttt aaa	628
Ile Pro Lys Tyr Val Lys Cys Asn Phe Asn Leu Ser Thr Tyr Phe Lys	
190 195 200	
act aat tct tct gat ttt gca caa ttt gaa cgt act tta ata ata gtt	676
Thr Asn Ser Ser Asp Phe Ala Gln Phe Glu Arg Thr Leu Ile Ile Val	
205 210 215	
ggt aaa tat tct tat gta tca tat tta gaa gga tgt aca gct tca tta	724
Gly Lys Tyr Ser Tyr Val Ser Tyr Leu Glu Gly Cys Thr Ala Ser Leu	
220 225 230	
tat aaa gaa tca caa tta cat gta gct ata gta gaa ata ata gta aaa	772
Tyr Lys Glu Ser Gln Leu His Val Ala Ile Val Glu Ile Ile Val Lys	
235 240 245	
gat tat ggt tat ata aaa tat tat aca tta caa aat tgg tat aga gga	820
Asp Tyr Gly Tyr Ile Lys Tyr Tyr Thr Leu Gln Asn Trp Tyr Arg Gly	
250 255 260 265	
gat tat tta ggt aat ggt ggt tta tat aat ttt aca act aaa cgt ggt	868
Asp Tyr Leu Gly Asn Gly Gly Leu Tyr Asn Phe Thr Thr Lys Arg Gly	
270 275 280	
ata tgt tta aat tat tca aaa tta gat tgg ata caa gtt gaa gta ggt	916
Ile Cys Leu Asn Tyr Ser Lys Leu Asp Trp Ile Gln Val Glu Val Gly	
285 290 295	
tcg att ata aca tgg aaa tac cct tct act att tta aaa ggt aaa ttt	964
Ser Ile Ile Thr Trp Lys Tyr Pro Ser Thr Ile Leu Lys Gly Lys Phe	
300 305 310	
tct att agt aat ttt tat tca ata tct ttt ata tca aat atg caa ata	1012
Ser Ile Ser Asn Phe Tyr Ser Ile Ser Phe Ile Ser Asn Met Gln Ile	
315 320 325	
gct gat act ggt agt aaa atg tat cat ata gga tct tat act aaa agt	1060
Ala Asp Thr Gly Ser Lys Met Tyr His Ile Gly Ser Tyr Thr Lys Ser	
330 335 340 345	
tat ata att tct aaa agt ata tct tta aat aac tca tta aat ata ttt	1108
Tyr Ile Ile Ser Lys Ser Ile Ser Leu Asn Asn Ser Leu Asn Ile Phe	
350 355 360	

-3-

```

aga ggt tta gta tat att aaa cct ttt tca tat aaa tct tat aat tat 1156
Arg Gly Leu Val Tyr Ile Lys Pro Phe Ser Tyr Lys Ser Tyr Asn Tyr
      365                      370                      375
act gaa tgt agt tct tta ata ttt ggt aat aat tct tta aca gta act 1204
Thr Glu Cys Ser Ser Leu Ile Phe Gly Asn Asn Ser Leu Thr Val Thr
      380                      385                      390
att cct tat ata aaa aat tat aat aat act agt tat gta aaa caa gaa 1252
Ile Pro Tyr Ile Lys Asn Tyr Asn Asn Thr Ser Tyr Val Lys Gln Glu
      395                      400                      405
gct ttt gtt tct aaa att gaa ath ata tat tta ttt tta tta atg caa 1300
Ala Phe Val Ser Lys Ile Glu Ile Ile Tyr Leu Phe Leu Leu Met Gln
      410                      415                      420                      425
cgt ggt tta agt att tca gag tct att tca tta tta att ata ggt ttt 1348
Arg Gly Leu Ser Ile Ser Glu Ser Ile Ser Leu Leu Ile Ile Gly Phe
      430                      435                      440
tgt tct gat att tat aat aaa tta ccg ttt gaa ttt aat tta gag ata 1396
Cys Ser Asp Ile Tyr Asn Lys Leu Pro Phe Glu Phe Asn Leu Glu Ile
      445                      450                      455
cct ata tta ttt tca tta aaa att aaa gat ata ttt aat taattaaat 1444
Pro Ile Leu Phe Ser Leu Lys Ile Lys Asp Ile Phe Asn
      460                      465                      470

```

&lt;210&gt; 2

&lt;211&gt; 1443

&lt;212&gt; DNA

&lt;213&gt; Synechocystis PCC6803

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1443)

&lt;400&gt; 2

```

atg agt tcc acc act gtt aaa aac ctg gtc aac caa ccc tac aaa tat 48
Met Ser Ser Thr Thr Val Lys Asn Leu Val Asn Gln Pro Tyr Lys Tyr
      1                      5                      10                      15
ggc ttt gtc acc aac att gaa gcg gat gct atc ccc cgt ggt ctg agt 96
Gly Phe Val Thr Asn Ile Glu Ala Asp Ala Ile Pro Arg Gly Leu Ser
      20                      25                      30
gaa gac gtg gtg cga ctc att tct gct aag aaa aat gaa ccc gaa ttc 144
Glu Asp Val Val Arg Leu Ile Ser Ala Lys Lys Asn Glu Pro Glu Phe
      35                      40                      45
atg ttg gat ttt cgc ctc cgg gcc tac cgg cat tgg ctg acc atg gcg 192
Met Leu Asp Phe Arg Leu Arg Ala Tyr Arg His Trp Leu Thr Met Ala
      50                      55                      60

```

-4-

gaa ccc act tgg ccg gcg gtg cat tat ccc ccc att gat tac caa gat	240
Glu Pro Thr Trp Pro Ala Val His Tyr Pro Pro Ile Asp Tyr Gln Asp	
65 70 75 80	
att att tac tac tcc gcc cct aag caa agt aag aaa aaa cta gaa agc	288
Ile Ile Tyr Tyr Ser Ala Pro Lys Gln Ser Lys Lys Lys Leu Glu Ser	
85 90 95	
tta gat gaa gtg gac cca gct ttg ttg gaa acc ttt gaa aaa tta ggg	336
Leu Asp Glu Val Asp Pro Ala Leu Leu Glu Thr Phe Glu Lys Leu Gly	
100 105 110	
att ccc cta tcg gag caa aaa cgt tta agt aat gtg gcg gta gat gcc	384
Ile Pro Leu Ser Glu Gln Lys Arg Leu Ser Asn Val Ala Val Asp Ala	
115 120 125	
att ttt gac agt gtt tcc att ggc aca act ttt aag gaa aag cta gcg	432
Ile Phe Asp Ser Val Ser Ile Gly Thr Thr Phe Lys Glu Lys Leu Ala	
130 135 140	
gaa gac ggg gta att ttc tgt tct att tct gaa gca ttg cag gaa cat	480
Glu Asp Gly Val Ile Phe Cys Ser Ile Ser Glu Ala Leu Gln Glu His	
145 150 155 160	
ccc gac ctg gtg caa aaa tat ttg ggc agt gtg gtg ccc acc gcc gac	528
Pro Asp Leu Val Gln Lys Tyr Leu Gly Ser Val Val Pro Thr Ala Asp	
165 170 175	
aac ttc ttt gcc gcc tta aac tct gct gta ttt agt gac ggt tcc ttt	576
Asn Phe Phe Ala Ala Leu Asn Ser Ala Val Phe Ser Asp Gly Ser Phe	
180 185 190	
gtt ttt att ccc aaa ggg gtg aag tgt ccc atg gaa ttg tcc acc tat	624
Val Phe Ile Pro Lys Gly Val Lys Cys Pro Met Glu Leu Ser Thr Tyr	
195 200 205	
ttc cgc att aat aat ggg gat acg ggg cag ttt gag cgg aca tta att	672
Phe Arg Ile Asn Asn Gly Asp Thr Gly Gln Phe Glu Arg Thr Leu Ile	
210 215 220	
att gcc gaa gaa ggg gct tcc gtt agc tat ttg gaa ggt tgt act gcg	720
Ile Ala Glu Glu Gly Ala Ser Val Ser Tyr Leu Glu Gly Cys Thr Ala	
225 230 235 240	
ccc atg tat gac acc aat caa ctt cat gcg gcg gtg gtg gaa ttg gta	768
Pro Met Tyr Asp Thr Asn Gln Leu His Ala Ala Val Val Glu Leu Val	
245 250 255	
gct cta gat aat gct gac att aaa tat tcc acc gta caa aac tgg tac	816
Ala Leu Asp Asn Ala Asp Ile Lys Tyr Ser Thr Val Gln Asn Trp Tyr	
260 265 270	
gct ggg gac gaa aat ggc aag ggc gga att tac aac ttt gtg act aaa	864
Ala Gly Asp Glu Asn Gly Lys Gly Gly Ile Tyr Asn Phe Val Thr Lys	
275 280 285	

-5-

cgg ggt cta tgt aaa gga gtt aat tcc aaa att tcc tgg acc caa gta	912
Arg Gly Leu Cys Lys Gly Val Asn Ser Lys Ile Ser Trp Thr Gln Val	
290 295 300	
gaa acc ggt tcc gcc att acc tgg aaa tac ccc agt tgt gtg cta gtt	960
Glu Thr Gly Ser Ala Ile Thr Trp Lys Tyr Pro Ser Cys Val Leu Val	
305 310 315 320	
ggg gat aat tcc gtc ggg gaa ttc tac tct att gct tta act aac aac	1008
Gly Asp Asn Ser Val Gly Glu Phe Tyr Ser Ile Ala Leu Thr Asn Asn	
325 330 335	
aaa cag caa gct gat acg gga act aaa atg att cac atc ggt aaa aat	1056
Lys Gln Gln Ala Asp Thr Gly Thr Lys Met Ile His Ile Gly Lys Asn	
340 345 350	
acc cgt agt atc att att tcc aaa ggc att tcc gct ggt aat tcc gcc	1104
Thr Arg Ser Ile Ile Ile Ser Lys Gly Ile Ser Ala Gly Asn Ser Ala	
355 360 365	
aac agt tac cgg ggt ttg gtg aaa atg gga cct aaa gcc cag ggc gct	1152
Asn Ser Tyr Arg Gly Leu Val Lys Met Gly Pro Lys Ala Gln Gly Ala	
370 375 380	
cgc aat tat tcc cag tgt gat tcc atg ctc att ggc gat cgg gca gcg	1200
Arg Asn Tyr Ser Gln Cys Asp Ser Met Leu Ile Gly Asp Arg Ala Ala	
385 390 395 400	
gct aat act ttt ccc tat att caa gtg gac aat aat acc gcc aaa gta	1248
Ala Asn Thr Phe Pro Tyr Ile Gln Val Asp Asn Asn Thr Ala Lys Val	
405 410 415	
gaa cat gaa gct tcc act tcc aaa att ggc gag gat caa ctc ttt tac	1296
Glu His Glu Ala Ser Thr Ser Lys Ile Gly Glu Asp Gln Leu Phe Tyr	
420 425 430	
ttt gcc caa cgg gga att tct gag gaa gat gcg gtg tcc atg cta gtc	1344
Phe Ala Gln Arg Gly Ile Ser Glu Glu Asp Ala Val Ser Met Leu Val	
435 440 445	
agc ggt ttc tgt aag gat gtg cta aac gaa tta ccc atg gaa ttt gcg	1392
Ser Gly Phe Cys Lys Asp Val Leu Asn Glu Leu Pro Met Glu Phe Ala	
450 455 460	
gcg gag gct gat aaa tta ctg agt ctc aaa cta gaa ggt act gtg ggt	1440
Ala Glu Ala Asp Lys Leu Leu Ser Leu Lys Leu Glu Gly Thr Val Gly	
465 470 475 480	
taa	1443

&lt;210&gt; 3

&lt;211&gt; 1527

&lt;212&gt; DNA

&lt;213&gt; Escherichia coli

&lt;220&gt;

-6-

&lt;221&gt; CDS

&lt;222&gt; (1)..(1527)

&lt;400&gt; 3

atg tgg ctg tgg cga aag ctt tgg ggt ata ggc ggt act atg tct cgt	48
Met Trp Leu Trp Arg Lys Leu Trp Gly Ile Gly Gly Thr Met Ser Arg	
1 5 10 15	
aat act gaa gca act gac gat gtc aaa acc tgg acc ggc ggc ccg ctg	96
Asn Thr Glu Ala Thr Asp Asp Val Lys Thr Trp Thr Gly Gly Pro Leu	
20 25 30	
aat tat aaa gaa gga ttc ttc acc cag tta gcc acc gat gag ctg gca	144
Asn Tyr Lys Glu Gly Phe Phe Thr Gln Leu Ala Thr Asp Glu Leu Ala	
35 40 45	
aag ggg ata aac gaa gag gtg gtg cgc gca att tcg gcg aag cgt aat	192
Lys Gly Ile Asn Glu Glu Val Val Arg Ala Ile Ser Ala Lys Arg Asn	
50 55 60	
gag ccg gag tgg atg ctg gag ttt cgt cta aac gcc tat cgc gca tgg	240
Glu Pro Glu Trp Met Leu Glu Phe Arg Leu Asn Ala Tyr Arg Ala Trp	
65 70 75 80	
ctg gag atg gaa gaa ccg cac tgg ttg aaa gcg cac tac gac aag ctg	288
Leu Glu Met Glu Glu Pro His Trp Leu Lys Ala His Tyr Asp Lys Leu	
85 90 95	
aat tat cag gat tac agc tac tac tca gca cca tcg tgc ggt aat tgt	336
Asn Tyr Gln Asp Tyr Ser Tyr Tyr Ser Ala Pro Ser Cys Gly Asn Cys	
100 105 110	
gac gac act tgc gcg tct gaa cct ggc gcg gtg cag caa act ggc gcg	384
Asp Asp Thr Cys Ala Ser Glu Pro Gly Ala Val Gln Gln Thr Gly Ala	
115 120 125	
aac gcc ttt tta agt aaa gag gtg gag gcg gcg ttt gag cag ttg ggc	432
Asn Ala Phe Leu Ser Lys Glu Val Glu Ala Ala Phe Glu Gln Leu Gly	
130 135 140	
gtt ccc gtg cgg gaa ggc aaa gag gtg gcg gtg gat gcc att ttc gac	480
Val Pro Val Arg Glu Gly Lys Glu Val Ala Val Asp Ala Ile Phe Asp	
145 150 155 160	
tca gtt tcg gtt gcc act act tat cgc gaa aaa ctg gcg gag cag gga	528
Ser Val Ser Val Ala Thr Thr Tyr Arg Glu Lys Leu Ala Glu Gln Gly	
165 170 175	
att att ttc tgt tcc ttt ggt gag gcg atc cac gat cac ccg gaa ctg	576
Ile Ile Phe Cys Ser Phe Gly Glu Ala Ile His Asp His Pro Glu Leu	
180 185 190	
gtg cgt aaa tat ctc ggc acc gtg gtg ccg ggg aat gac aac ttc ttt	624
Val Arg Lys Tyr Leu Gly Thr Val Val Pro Gly Asn Asp Asn Phe Phe	
195 200 205	



-7-

gcc gcg ctt aat gcg gcg gta gcc tct gat ggt acg ttt att tat gtg	672
Ala Ala Leu Asn Ala Ala Val Ala Ser Asp Gly Thr Phe Ile Tyr Val	
210 215 220	
cct aaa ggc gtg cgc tgc ccg atg gaa ctt tcc acc tat ttt cgc att	720
Pro Lys Gly Val Arg Cys Pro Met Glu Leu Ser Thr Tyr Phe Arg Ile	
225 230 235 240	
aac gca gaa aaa acc ggg cag ttt gag cgc acc att ctg gtg gcc gac	768
Asn Ala Glu Lys Thr Gly Gln Phe Glu Arg Thr Ile Leu Val Ala Asp	
245 250 255	
gaa gac agc tac gtc agc tac att gaa ggc tgt tcc gct ccg gtg cgt	816
Glu Asp Ser Tyr Val Ser Tyr Ile Glu Gly Cys Ser Ala Pro Val Arg	
260 265 270	
gac agc tat cag tta cac gcg gca gtg gtg gaa gtc atc atc cat aaa	864
Asp Ser Tyr Gln Leu His Ala Ala Val Val Glu Val Ile Ile His Lys	
275 280 285	
aac gcc gag gtg aaa tat tcc acg gta caa aac tgg ttt cct ggc gat	912
Asn Ala Glu Val Lys Tyr Ser Thr Val Gln Asn Trp Phe Pro Gly Asp	
290 295 300	
aac aac acc ggc ggt att ctc aac ttc gtc acc aag cgt gct ttg tgc	960
Asn Asn Thr Gly Gly Ile Leu Asn Phe Val Thr Lys Arg Ala Leu Cys	
305 310 315 320	
gaa ggc gaa aac agc aaa atg tca tgg acg caa tca gaa acc ggg tca	1008
Glu Gly Glu Asn Ser Lys Met Ser Trp Thr Gln Ser Glu Thr Gly Ser	
325 330 335	
gcg att acg tgg aaa tat ccc agc tgc att ttg cgc ggc gat aac tcc	1056
Ala Ile Thr Trp Lys Tyr Pro Ser Cys Ile Leu Arg Gly Asp Asn Ser	
340 345 350	
att ggt gag ttt tac tca gtg gcg ctg acc agc ggt cat cag caa gcg	1104
Ile Gly Glu Phe Tyr Ser Val Ala Leu Thr Ser Gly His Gln Gln Ala	
355 360 365	
gat acc ggc acc aag atg atc cac atc ggt aaa aac acc aaa tcg acc	1152
Asp Thr Gly Thr Lys Met Ile His Ile Gly Lys Asn Thr Lys Ser Thr	
370 375 380	
att atc tcg aaa ggg atc tct gcc gga cat agt cag aac agt tat cgc	1200
Ile Ile Ser Lys Gly Ile Ser Ala Gly His Ser Gln Asn Ser Tyr Arg	
385 390 395 400	
ggc tta gtg aaa atc atg ccg acg gca acc aat gcg cgc aat ttc act	1248
Gly Leu Val Lys Ile Met Pro Thr Ala Thr Asn Ala Arg Asn Phe Thr	
405 410 415	
cag tgc gac tca atg ctg att ggc gct aat tgt ggg gcg cat acc ttc	1296
Gln Cys Asp Ser Met Leu Ile Gly Ala Asn Cys Gly Ala His Thr Phe	
420 425 430	

-8-

ccg	tat	gtt	gag	tgt	cgt	aac	aat	agt	gcg	caa	ctg	gaa	cac	gag	gca	1344
Pro	Tyr	Val	Glu	Cys	Arg	Asn	Asn	Ser	Ala	Gln	Leu	Glu	His	Glu	Ala	
		435					440				445					
acg	aca	tca	cgt	att	ggg	gaa	gat	caa	ctg	ttt	tac	tgc	ctg	caa	cgc	1392
Thr	Thr	Ser	Arg	Ile	Gly	Glu	Asp	Gln	Leu	Phe	Tyr	Cys	Leu	Gln	Arg	
		450				455					460					
ggg	atc	agc	gaa	gaa	gac	gcc	atc	tcg	atg	att	gtt	aac	ggg	ttc	tgc	1440
Gly	Ile	Ser	Glu	Glu	Asp	Ala	Ile	Ser	Met	Ile	Val	Asn	Gly	Phe	Cys	
		465			470				475					480		
aaa	gac	gtg	ttc	tcg	gag	ctg	ccg	ttg	gaa	ttt	gcc	gtt	gaa	gca	caa	1488
Lys	Asp	Val	Phe	Ser	Glu	Leu	Pro	Leu	Glu	Phe	Ala	Val	Glu	Ala	Gln	
			485				490				495					
aaa	ctc	ctc	gcc	atc	agt	ctt	gaa	cac	agc	gtc	gga	taa				1527
Lys	Leu	Leu	Ala	Ile	Ser	Leu	Glu	His	Ser	Val	Gly					
			500				505									

1344  
 1392  
 1440  
 1488  
 1527

-28-

Claims

1. An inhibitor of ycf 24 gene product expression and/or activity for use in a method of treatment of infection of the human or animal body by an organism comprising said gene.

2. An inhibitor according to claim 1 for use in a method of treatment of malaria.

10

3. A method of inhibiting the growth of an organism comprising the ycf 24 gene, which method comprises contacting the organism ex vivo with an inhibitor of expression and/or activity of the gene product.

15

4. A method of identifying a compound that inhibits the growth of an organism comprising the ycf 24 gene, the method comprising

(i) contacting a test compound with the ycf 24 gene product, and

20

(ii) determining whether the test compound inhibits the activity of or binds to the product, any such binding or inhibition being indicative that the compound inhibits the growth of the organism.

25

5. A method of identifying a compound that inhibits the growth of an organism comprising the ycf 24 gene, the method comprising

(i) contacting a test compound with a test construct comprising a ycf 24 promoter operably linked to a coding sequence,

30

(ii) determining whether the test compound inhibits expression driven by the promoter, any such inhibition being indicative that the compound inhibits the growth of the organism.

35

-29-

6. A method according to claim 4 or 5 in which the organism is a malaria parasite.

7. A method of inhibiting the growth of an organism comprising the *ycf 24* gene, said method comprising contacting the organism *ex vivo* with a compound identified by the method of any one of claims 4 to 6.

8. Use of a compound identified by the method of any one of claims 4 to 6 for the manufacture of a medicament for the treatment of an infection by an organism comprising the *ycf 24* gene.

9. A pharmaceutical composition comprising an inhibitor of *ycf 24* gene product expression and/or activity or a compound identified by the method of any one of claims 4 to 6 and a pharmaceutically acceptable carrier or diluent.

10. A method of preventing or treating infection by a unicellular organism comprising the *ycf 24* gene in a patient, said method comprising administering to the patient an inhibitor of *ycf 24* gene product expression and/or activity or a compound identified by the method of any one of claims 4 to 6.

11. A method according to claim 10 in which the organism is a malaria parasite.

Fig.1a.




Fig.1b.





Fig.1c.



Fig.1d.



3/4

Fig.2.




Fig.3a.





Fig.3b.





RULE 63 (37 C.F.R. 1.63)  
**DECLARATION AND POWER OF ATTORNEY  
 FOR PATENT APPLICATION  
 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled INHIBITORS OF YCF24 AS ANTIMALARIALS

the specification of which (check applicable box(es)).

☐ is attached hereto

☐ was filed on

☒ was filed as PCT international application No. PCT/GB 99/03180 on 22<sup>nd</sup> September 1999

and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 C.F.R. 1.56(a). I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application.

Prior Foreign Application(s):

Application Number	Country	Day/Month/Year Filed
9820658.4	United Kingdom	22 <sup>nd</sup> September 1998

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56(a) which occurred between the filing date of the prior applications and the national or PCT international filing date of this application.

Prior U.S./PCT Application(s):

Application Serial No.	Day/Month/Year Filed	Status patented, pending, abandoned
PCT/GB 99/03180	22 <sup>nd</sup> September 1999	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Nixon & Vanderhye P.C., 1100 North Glebe Road, 8th Floor, Arlington, Virginia 22201-4714, telephone number (703) 816-400 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Paul J. Henon, 33626; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205.

1) Inventor's Signature Robert Wilson Date 27.04.01

Inventor's Name (typed) Robert John Macleod WILSON British  
First Middle Initial Family Name Citizenship

Residence (City) London (State/Foreign Country) United Kingdom GBX

Post Office Address 14 Lyndhurst Avenue, Mill Hill, London NW7 2AB United Kingdom Zip Code NW7 2AB

2) Inventor's Signature Conrad Mullineux Date 8/5/01

Inventor's Name (typed) Conrad William MULLINEUX British  
First Middle Initial Family Name Citizenship


Residence (City) Barnet (State/Foreign Country) Hertfordshire United Kingdom GBX

Post Office Address 112 Mays Lane, Barnet, Hertfordshire EN5 2LS United Kingdom Zip Code EN5 2LS

FOR ADDITIONAL INVENTORS, check box [X] and attach sheet with same information and signature and date for each.

3) Inventor's Signature *Anna* Date 27.04.01  
Inventor's Name (typed) Anna Elizabeth LAW British  
First Middle-Initial Family Name Citizenship  
Residence (City) Westbrook, Margate (State/Foreign Country) Kent United Kingdom GBX  
Post Office Address 175 Canterbury Road, Westbrook, Margate, Kent CT9 5BY United Kingdom Zip Code CT9 5BY

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ Scanned copy is best available. Drawings -